Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of GS-9674 in Primary Sclerosing Cholangitis Without Cirrhosis
2016-002442-23Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing GS-9674 with Placebo (2 arms). Primary endpoint: Safety and tolerability of GS-9674. Started Nov 2016; status: completed.
02
Drugs
cilofexor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2016-002442-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002442-23.